Literature DB >> 28359744

Activation of the kynurenine pathway predicts poor outcome in patients with clear cell renal cell carcinoma.

Giuseppe Lucarelli1, Monica Rutigliano2, Matteo Ferro3, Andrea Giglio2, Angelica Intini2, Francesco Triggiano2, Silvano Palazzo2, Margherita Gigante4, Giuseppe Castellano4, Elena Ranieri5, Carlo Buonerba6, Daniela Terracciano7, Francesca Sanguedolce8, Anna Napoli9, Eugenio Maiorano9, Franco Morelli10, Pasquale Ditonno2, Michele Battaglia2.   

Abstract

OBJECTIVE: To investigate the expression of the kynurenine (KYN) pathway components and the prognostic role of the KYN-to-tryptophan ratio (KTR) in a cohort of patients with clear cell renal cell carcinoma (ccRCC).
MATERIALS AND METHODS: The expression of KYN pathway components was investigated by tissue microarray-based immunohistochemistry, indirect immunofluorescence, and confocal microscopy analysis in 100 ccRCC cases and 30 normal renal samples. The role of this pathway in sustaining cancer cell proliferation, migration, and chemoresistance was evaluated. In addition, tryptophan and KYN concentrations and their ratio were measured in serum of 195 patients with ccRCC using a sandwich enzyme-linked immunosorbent assay. The role of KTR as a prognostic factor for ccRCC cancer-specific survival (CSS) and progression-free survival (PFS) was assessed.
RESULTS: Tissue microarray-based immunohistochemistry and indirect immunofluorescence staining showed an increased signal for KYN pathway components in ccRCC. Kaplan-Meier curves showed significant differences in CSS and PFS among groups of patients with high vs. low KTR. In particular, patients with high KTR values had a 5-year survival rate of 76.9% as compared with 92.3% for subjects with low levels (P  < 0.0001). Similar findings were observed for PFS (72.8% vs. 96.8% at 5y). At multivariate analysis, KTR was an independent adverse prognostic factor for CSS (hazard ratio  = 1.24, P  =  0.001), and PFS (hazard ratio  =  1.14, P  =  0.001).
CONCLUSIONS: The involvement of the KYN pathway enzymes and catabolites in ccRCC occurs via both immune and nonimmune mechanisms. Our data suggest that KTR could serve as a marker of ccRCC aggressiveness and as a prognostic factor for CSS and PFS.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Aryl hydrocarbon receptor; Cancer metabolism; Indoleamine 2,3-dioxygenase; Kynurenine; Renal cell carcinoma

Mesh:

Substances:

Year:  2017        PMID: 28359744     DOI: 10.1016/j.urolonc.2017.02.011

Source DB:  PubMed          Journal:  Urol Oncol        ISSN: 1078-1439            Impact factor:   3.498


  23 in total

1.  Phase 1 investigation of lenalidomide/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma.

Authors:  James L Rubenstein; Huimin Geng; Eleanor J Fraser; Paul Formaker; Lingjing Chen; Jigyasa Sharma; Phoebe Killea; Kaylee Choi; Jenny Ventura; John Kurhanewicz; Clifford Lowell; Jimmy Hwang; Patrick Treseler; Penny K Sneed; Jing Li; Xiaomin Wang; Nianhang Chen; Jon Gangoiti; Pamela N Munster; Bertil Damato
Journal:  Blood Adv       Date:  2018-07-10

2.  Tryptophan catabolism in epithelial ovarian carcinoma.

Authors:  Lynelle P Smith; Benjamin G Bitler; Jennifer K Richer; Jessica L Christenson
Journal:  Trends Cancer Res       Date:  2019

Review 3.  Obesity and Cancer: Existing and New Hypotheses for a Causal Connection.

Authors:  Trevor W Stone; Megan McPherson; L Gail Darlington
Journal:  EBioMedicine       Date:  2018-02-27       Impact factor: 8.143

4.  Integrated multi-omics characterization reveals a distinctive metabolic signature and the role of NDUFA4L2 in promoting angiogenesis, chemoresistance, and mitochondrial dysfunction in clear cell renal cell carcinoma.

Authors:  Giuseppe Lucarelli; Monica Rutigliano; Fabio Sallustio; Domenico Ribatti; Andrea Giglio; Martina Lepore Signorile; Valentina Grossi; Paola Sanese; Anna Napoli; Eugenio Maiorano; Cristina Bianchi; Roberto A Perego; Matteo Ferro; Elena Ranieri; Grazia Serino; Lauren N Bell; Pasquale Ditonno; Cristiano Simone; Michele Battaglia
Journal:  Aging (Albany NY)       Date:  2018-12-11       Impact factor: 5.682

5.  A comparison of the prognosis of papillary and clear cell renal cell carcinoma: Evidence from a meta-analysis.

Authors:  Jun Deng; Lei Li; Haimei Xia; Ju Guo; Xin Wu; Xiaorong Yang; Yanyan Hong; Qingke Chen; Jieping Hu
Journal:  Medicine (Baltimore)       Date:  2019-07       Impact factor: 1.817

6.  PTX3 modulates the immunoflogosis in tumor microenvironment and is a prognostic factor for patients with clear cell renal cell carcinoma.

Authors:  Giuseppe Stefano Netti; Giuseppe Lucarelli; Federica Spadaccino; Giuseppe Castellano; Margherita Gigante; Chiara Divella; Maria Teresa Rocchetti; Federica Rascio; Vito Mancini; Giovanni Stallone; Giuseppe Carrieri; Loreto Gesualdo; Michele Battaglia; Elena Ranieri
Journal:  Aging (Albany NY)       Date:  2020-04-28       Impact factor: 5.682

Review 7.  Multidiscipline Immunotherapy-Based Rational Combinations for Robust and Durable Efficacy in Brain Metastases from Renal Cell Carcinoma.

Authors:  Hye-Won Lee
Journal:  Int J Mol Sci       Date:  2021-06-11       Impact factor: 5.923

8.  Efficacy of raman spectroscopy in the diagnosis of kidney cancer: A systematic review and meta-analysis.

Authors:  Hongyu Jin; Xiao He; Hui Zhou; Man Zhang; Qingqing Tang; Lede Lin; Jianqi Hao; Rui Zeng
Journal:  Medicine (Baltimore)       Date:  2020-07-02       Impact factor: 1.817

9.  Discriminating malignant and benign clinical T1 renal masses on computed tomography: A pragmatic radiomics and machine learning approach.

Authors:  Johannes Uhlig; Lorenz Biggemann; Manuel M Nietert; Tim Beißbarth; Joachim Lotz; Hyun S Kim; Lutz Trojan; Annemarie Uhlig
Journal:  Medicine (Baltimore)       Date:  2020-04       Impact factor: 1.817

Review 10.  Metabolic Pathways in Kidney Cancer: Current Therapies and Future Directions.

Authors:  W Kimryn Rathmell; Jeffrey C Rathmell; W Marston Linehan
Journal:  J Clin Oncol       Date:  2018-10-29       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.